# Sorafenib Plus Tegafur-uracil (UFT) Versus Sorafenib as First Line Systemic Treatment for Patients With Advanced Stage HCC, Unresectable & Not Eligible for Local Ablation and/or TACE

> **NCT01539018** · PHASE2 · TERMINATED · sponsor: **Egyptian Society of Liver Cancer** · enrollment: 77 (actual)

## Conditions studied

- Advanced Hepatocellular Carcinoma

## Interventions

- **DRUG:** Sorafenib
- **DRUG:** sorafenib plus tegafur-uracil

## Key facts

- **NCT ID:** NCT01539018
- **Lead sponsor:** Egyptian Society of Liver Cancer
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-01
- **Primary completion:** 2015-01
- **Final completion:** 2015-01
- **Target enrollment:** 77 (ACTUAL)
- **Why stopped:** After interim results data showed no evidence of a difference between both groups
- **Last updated:** 2015-08-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01539018

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01539018, "Sorafenib Plus Tegafur-uracil (UFT) Versus Sorafenib as First Line Systemic Treatment for Patients With Advanced Stage HCC, Unresectable & Not Eligible for Local Ablation and/or TACE". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01539018. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*